Quest PharmaTech (CVE:QPT) Hits New 1-Year Low – Should You Sell?

Quest PharmaTech Inc. (CVE:QPT) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 2000 shares changing hands. The stock had previously closed at C$0.03.

Quest PharmaTech Stock Down 20.0%

The firm has a 50-day simple moving average of C$0.03 and a 200 day simple moving average of C$0.03. The company has a market capitalization of C$3.38 million, a PE ratio of 0.67 and a beta of 0.00. The company has a debt-to-equity ratio of 4.35, a current ratio of 0.40 and a quick ratio of 0.52.

About Quest PharmaTech

Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.